



# Neuromuscular presentations in patients with COVID-19

Vimal Kumar Paliwal<sup>1</sup> · Ravindra Kumar Garg<sup>2</sup> · Ankit Gupta<sup>1</sup> · Nidhi Tejan<sup>3</sup>

Received: 7 July 2020 / Accepted: 1 September 2020 / Published online: 15 September 2020  
© Fondazione Società Italiana di Neurologia 2020

## Abstract

COVID-19 is caused by the coronavirus SARS-CoV-2 that has an affinity for neural tissue. There are reports of encephalitis, encephalopathy, cranial neuropathy, Guillain-Barrè syndrome, and myositis/rhabdomyolysis in patients with COVID-19. In this review, we focused on the neuromuscular manifestations of SARS-CoV-2 infection. We analyzed all published reports on SARS-CoV-2-related peripheral nerve, neuromuscular junction, muscle, and cranial nerve disorders. Olfactory and gustatory dysfunction is now accepted as an early manifestation of COVID-19 infection. Inflammation, edema, and axonal damage of olfactory bulb have been shown in autopsy of patients who died of COVID-19. Olfactory pathway is suggested as a portal of entry of SARS-CoV-2 in the brain. Similar to involvement of olfactory bulb, isolated oculomotor, trochlear and facial nerve has been described. Increasing reports Guillain-Barrè syndrome secondary to COVID-19 are being published. Unlike typical GBS, most of COVID-19-related GBS were elderly, had concomitant pneumonia or ARDS, more prevalent demyelinating neuropathy, and relatively poor outcome. Myalgia is described among the common symptoms of COVID-19 after fever, cough, and sore throat. Duration of myalgia may be related to the severity of COVID-19 disease. Few patients had muscle weakness and elevated creatine kinase along with elevated levels of acute-phase reactants. All these patients with myositis/rhabdomyolysis had severe respiratory complications related to COVID-19. A handful of patients with myasthenia gravis showed exacerbation of their disease after acquiring COVID-19 disease. Most of these patients recovered with either intravenous immunoglobulins or steroids.

**Keywords** SARS-CoV-2 · COVID-19 · Coronavirus · Anosmia · Ageusia · Guillain-Barrè syndrome · Myositis · Rhabdomyolysis

The COVID-19 pandemic is caused by SARS-CoV-2, a member of the Coronavirinae subfamily. The coronaviruses are classified in four genera: alpha, beta, gamma, and delta coronaviruses [1]. The world has seen three large pandemics

in the last 2 decades. The first pandemic originated in Guangdong, China (2002–2003) caused by SARS-CoV-1, and the second pandemic originated in Saudi Arabia (2012), caused by MERS CoV [2–4]. Both pandemics produced severe acute respiratory syndrome (SARS) in thousands of people and produced case fatality rate of 9.6% and 34.4%, respectively [5]. The current pandemic is caused by novel coronavirus named as SARS-CoV-2 that originated in Wuhan, China, in December 2019. As of July 2020, COVID-19 has affected 14.3 million people and produced more than six hundred thousand deaths. All three viruses that produced these three pandemics are beta coronaviruses and share a homologous genomic sequence. The SARS-CoV-2 has a higher affinity for angiotensin-converting enzyme receptor 2 (ACE-2) that is expressed on endothelial cells and neurons. This explains a higher neuro-invasive capacity of SARS-CoV-2 as compared with previous coronaviruses [6].

A number of neurological manifestations of SARS-CoV-2 have been reported. These include encephalitis, acute disseminated encephalomyelitis (ADEM), encephalopathy, steroid-responsive encephalopathy, posterior reversible encephalopathy

✉ Vimal Kumar Paliwal  
dr\_vimalkpaliwal@rediffmail.com

Ravindra Kumar Garg  
garg50@yahoo.com

Ankit Gupta  
drankitgupta90@gmail.com

Nidhi Tejan  
getnids@gmail.com

<sup>1</sup> Department of Neurology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP 226014, India

<sup>2</sup> Department of Neurology, King George Medical University, Lucknow, UP, India

<sup>3</sup> Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, UP 226014, India

syndrome (PRES), and meningitis. The neuromuscular manifestations like hyposmia/ageusia, ophthalmoparesis, facial paresis, Guillain-Barré syndrome, symmetrical neuropathy, critical-illness myopathy and neuropathy, myalgia, myositis, and rhabdomyolysis have also been described in patients secondary to COVID-19. In this review, we focused on the neuromuscular manifestation of SARS-CoV-2 infection.

## Methods

We analyzed all published reports on COVID-19-associated neuromuscular manifestations. We performed an extensive search of PubMed, Google Scholar, Scopus, and preprint databases (medRxiv and bioRxiv). We identified isolated case reports, case series, and cohort studies. We used search terms, “COVID-19 and Guillain-Barré syndrome, hyposmia, myositis, rhabdomyolysis, neuropathy” and “SARS-CoV-2 and Guillain-Barré syndrome, hyposmia, myositis, rhabdomyolysis, neuropathy”. Full-text articles were acquired from journals’ websites. We analyzed demographic, clinical, CSF, and neuroimaging characteristics of patients presenting with COVID-19-related peripheral nervous system manifestations. We also discuss the pathogenesis of COVID-19-associated neuropathy and muscle involvement. The last search was done on 2 July 2020.

## Search results

We identified 96 studies of COVID-19-related myalgia. After exclusion of descriptive reviews, data in other than English language, and duplicate studies, we selected 13 studies and 2 meta-analysis comprising of 10 and 55 studies, respectively (Table 1) [7–21].

Similarly, we identified 8 case reports (9 patients) with keywords COVID-19 and myositis/rhabdomyolysis (Table 2) [22–29].

Two reports described exacerbation of myasthenia gravis in six patients secondary to COVID-19 infection [30, 31].

We identified 34 reports comprising 39 patients with Guillain-Barré syndrome and five patients with Miller-Fisher syndrome (Tables 3 and 4) [32–65].

In addition to GBS and MFS, we also included three reports of six patients who developed symmetrical or asymmetrical neuropathy (Table 5) [66–68].

We identified 2 meta-analyses of 24 and 21 studies/case reports respectively that described patients with olfactory/gustatory dysfunction [69, 70]. In addition, we describe 11 studies that evaluated olfactory/gustatory dysfunction in COVID-19 patients (Table 6) [71–81].

We also included 5 reports (6 patients) of isolated cranial neuropathy in COVID-19 patients (Table 6) [82–87].

## Myalgia

A meta-analysis of clinical characteristics by Long-quan Li et al. (10 studies, 1995 patients, published between December 2019 and February 2020) showed that prevalence of myalgia was 35.8% (range 11 to 50%). Frequency of other symptoms was fever (88.5%), cough (68.6%), expectoration (28.2%) and dyspnoea (21.9%). Less common symptoms were dizziness, diarrhoea, nausea, and vomiting. They found a fatality rate of 5% and discharge rate of 52% in COVID-19 patients [10]. Another meta-analysis (55 studies, 8697 patients, published between 1 January 2020 and 16 March 2020) showed myalgia in 21.9% COVID-19 patients. Other common symptoms were fever (78.4%), cough (58.3%), fatigue (34%), expectoration (23.7%), anorexia (22.9%), chest tightness (22.9%), and dyspnoea (20.6%). Patients diagnosed before January 31 had higher prevalence of fever and cough. The authors concluded that as the pandemic grew, the prevalence of atypical symptoms increased [15]. In a study of olfactory and gustatory function in COVID-19 patients by Lechien et al., more than 50% patients had myalgia [76]. In a retrospective study by Zhang et al., muscle ache was one of the independent predictors for unimprovement in patients with COVID-19. The other independent predictors were being male, severe COVID-19 condition, expectoration, and decreased albumin at admission [87]. In a cohort of pregnant patients, the frequency of constitutional symptoms of COVID-19 infection was similar to the general population. The study did not find any vertical transmission of COVID-19 infection [88]. In a study comparing the clinical features of SARS-CoV-1 and COVID-19 infection, fever and cough were equally prevalent in both infections but the myalgia and diarrhoea were less common in COVID-19 as compared with SARS-CoV-1 [89]. In a study of 1420 European patients with COVID-19, elderly patients were more likely to have myalgia, fatigue, and fever as compared with younger patients who had higher propensity to acquire symptoms related to ear, nose, and throat [13]. As compared with COVID-19-negative patients, COVID-19-positive patients with respiratory illness reported longer symptom duration (median 7 vs. 3 days), higher prevalence of fever (82% vs. 44%), fatigue (85% vs. 50%), and myalgias (61% vs 27%) [90]. Myalgia persisted at the median time of 23 days of cessation of viral shedding. The other symptoms that persisted at the time of cessation of viral shedding were cough, anosmia, ageusia, and sore throat [91].

## Myositis/rhabdomyolysis

Nine patients (age range 16 to 88 years, all males) with COVID-19-related myositis/rhabdomyolysis were reported [22–29]. Eight patients presented with generalized or limb weakness. Myalgias were present in four patients. One patient who did not have muscle weakness presented with myalgia,

**Table 1** Studies showing prevalence of myalgia and other presenting symptoms in patients with COVID-19

| Author/year                     | Meta-analysis/study               | Prevalence of myalgia (%) | Other presenting symptoms   |
|---------------------------------|-----------------------------------|---------------------------|---|
| Huang et al./Feb, 2020 [7]      | Study (N = 41)                    | 44                        | Fever 98%, cough 76%, dyspnoea 55%, expectoration 28%, headache 8%, haemoptysis 5%, diarrhoea 3%  |
| Xu et al./Feb, 2020 [8]         | Study (N = 62)                    | 52                        | Fever 77%, cough 81%, expectoration 56%, headache 34%, diarrhoea 8%, dypnoea 3%   |
| Liu et al./March, 2020 [9]      | Study (N = 30 HCW with pneumonia) | 70                        | Cough 83.33%, fever 76.67%, headache 53.33%, GI symptoms 30%, dypnoea 46.67%  |
| Li et al./March, 2020 [10]      | Meta-analysis (N = 1995)          | 35.8                      | Fever 88.5%, cough 68.6%, expectoration 28.2%, Dyspnoea 21.9%, headache 12.1%   |
| Wang et al./Apr, 2020 [11]      | Study (N = 80, HCW)               | 23.75                     | Fever 81.25%, cough 58.75%, fatigue 35%, expectoration 23.75%, diarrhoea 18.75%   |
| Wei et al./Apr, 2020 [12]       | Study (N = 14, pneumonia)         | 100                       | Fever 86%, dry cough 71%  |
| Lechien et al./Apr, 2020 [13]   | Study (N = 1420)                  | 62.5                      | Headache 70.3%, anosmia 70.2%, nasal obstruction 67.8%, cough 63.2%, asthenia 63.3%, rhinorrhoea 60.1%, gustatory dysfunction 54.2%, sore throat 52.9%, fever 45.4% |
| Lai et al./May, 2020 [14]       | Study (N = 110 HCW)               | 45.5                      | Fever 60.9%, cough 56.4%, sore throat 50%   |
| Zhu et al./May, 2020 [15]       | Meta-analysis                     | 21.9                      | Fever 78.4%, cough 58.3%, fatigue 34%, expectoration 23.7%, anorexia 22.9%, chest tightness 22.9%, dyspnoea 20.6%   |
| Lapostolle et al./May 2020 [16] | Study (N = 1487)                  | 57                        | Fever 92.5%, dry cough 94%, headache 55%, asthenia 28%, ageusia 28%, chest pain 21%, hemoptysis 3%  |
| Chen et al./June, 2020 [17]     | Study (N = 38, fatalities)        | 15.79                     | Fever 65.78%, cough 42.10%, dyspnoea 60.52%, chest tightness 26.31%   |
| Korkmaz et al./June, 2020 [18]  | Study (N = 80, children)          | 19                        | Fever (58%), cough (52%)  |
| Reilly et al./June, 2020 [19]   | Study (N = 14)                    | 67                        | Dyspnea (77%), fatigue (100%), diarrhoea (67%)  |
| Gaur et al./July, 2020 [20]     | Study (N = 26)                    | 38.46                     | Fever (61.54%), sore throat (53.84%), cough (42.3%), dyspnea (23.07%)   |
| Aggarwal et al./July, 2020 [21] | Study (N = 32, ARDS)              | 43.75                     | Dyspnea (90%), cough (84.4%), fever (68%)   |

ARDS acute respiratory distress syndrome, HCW health care worker

fever, and dyspnoea [26]. One patient presented with repetitive muscle twitching along with tingling and numbness in the legs [28]. Only one patient had cola-coloured urine [29]. Three patients passed red blood cells in the urine. All patients had elevated CPK levels [28, 29]. One patient who presented with cola-coloured urine had most elevated CPK level of 427,656 IU/L. All patients had elevated levels of CRP, LDH, and serum ferritin. Six patients had abnormalities on chest imaging like ground-glass opacities, pneumonia, pleural effusion, or multifocal opacities. Two patients required mechanical ventilation [22, 29]. Five patients improved with conservative management.

In addition to myositis and rhabdomyolysis, there is a report of six COVID-19 patients with critical-illness myopathy. All six patients had acute flaccid quadriplegia. Electrophysiological tests revealed a myopathic pattern. They had mildly elevated creatine kinase and all patients had a good outcome [92]. Cachexia and sarcopenia have also been described in patients affected by COVID-19 [93].

## Myasthenia gravis

There are no reports of de-novo occurrence of myasthenia gravis secondary to COVID-19. However, there are two reports of 5 and 1 patients respectively (age range 42–90 years, 4 females) of COVID-19 infection-related exacerbation of the pre-existing myasthenia gravis [30, 31]. Five patients had anti-acetylcholine receptor antibody-positive myasthenia gravis whereas one patient had muscle-specific kinase (MuSK)-positive myasthenia gravis. All patients had exacerbation of myasthenic symptoms after sore throat, fever, cough, and shortness of breath in variable combination. Two patients required mechanical ventilation. Steroids were continued in 4 patients. Two patients received intravenous immunoglobulins. Two patients were taking mycophenolate mofetil that was transiently stopped in view of COVID-19 infection. MMF was resumed in both patients after discharge from the hospital. Five patients improved, and one patient was on mechanical ventilator at the time of publication of the report.

**Table 2** Demographic, clinical, and laboratory parameters and outcome of patients with myositis/rhabdomyolysis secondary to COVID-19

| Reference/<br>country                   | Age/sex       | Clinical presentation   | Respiratory<br>involvement | Blood parameters   | Chest imaging  | Neuroimaging   | Treatment/outcome   |
|---|---------------|---|----------------------------|--|--|--|---|
| Uysal<br>et al./Turkey<br>[22]          | 60/M          | Myalgia, fatigue  | Yes                        | Raised CK, CRP, LDH, ferritin  | B/L<br>ground-glass<br>opacities                           | NA   | HCQ, anti-viral, azithromycin   |
| Valente-Acosta<br>et al./Mexico<br>[23] | 71/M          | Fever, dyspnea, cough,<br>myalgia, generalized<br>weakness                        | Yes                        | CK 8720 U/L, raised myoglobin,<br>creatinine, LDH, IL-6, ferritin                        | B/L<br>ground-glass<br>opacities                           | NA   | Ventilator, HCQ, anti-viral,<br>tocilizumab   |
| Beydon<br>et al./France<br>[24]         | NA            | Myalgias, lower limb<br>proximal weakness, fever                                  | No                         | Raised CPK, CRP,<br>lymphocytopenia  | B/L<br>ground-glass<br>opacities with contrast enhancement | B/L external obturator muscle<br>and quadriceps oedema | NA/critical   |
| Suwanwongse<br>et al./USA<br>[25]       | 88/M          | Acute onset B/L thighs pain<br>and weakness, fever, dry<br>cough                  | No                         | Raised CPK, LDH  | Left pleural<br>effusion                                   | Normal   | IV fluids, furosemide,<br>HCQ/improved  |
| Zhang<br>et al./USA<br>[26]             | 38/M          | Fever, dyspnoea, myalgia  | Yes                        | Raised CPK, CRP, LDH   | Right upper and<br>middle lobe<br>consolidation            | NA   | Azithromycin, IV fluids, HCQ,<br>doxycycline/improved   |
| Jin et al./China<br>[27]                | 60 years<br>M | Fever, cough, pain, and<br>weakness in B/L lower<br>limbs                         | Yes                        | Raised CPK, myoglobin, CRP,<br>LDH, leukopenia   | B/L<br>ground-glass<br>opacities                           | NA   | Oxygen inhalation, opनाविर,<br>moxifloxacin, IV fluids, gamma<br>globulin, plasma<br>transfusion/improved |
| Chan<br>et al./USA<br>[28]              | 75 years<br>M | Generalized weakness,<br>reduced appetite   | Yes                        | Elevated CK, AST, ALT,<br>troponin, LDH, CRP, D dimer,<br>ferritin hematuria, normal EKG | Left lower lobe<br>patchy<br>opacity                       | NA   | Antibiotics,<br>hydroxychloroquine/improved   |
| Gefen<br>et al./USA<br>[29]             | 71 years<br>M | Repetitive leg twitching,<br>generalized weakness,<br>tingling/numbness legs      | Yes                        | Elevated CK, BUN, creatinine,<br>troponin, hematuria, EKG-AF                             | Multifocal<br>pneumonia                                    | Old lacunar infarct                                    | Antibiotics, hydroxychloroquine,<br>heparin, IV fluids/on mechanical<br>ventilator                        |
|   | 16 years<br>M | Fever, myalgia, shortness of<br>breath, cola-coloured<br>urine, muscle tenderness | No                         | Elevated CK (427,656 U/L), AST, NA<br>ALT, procalcitonin, LDH, CRP                       | NA   | NA   | IV fluids/improved  |

AST aspartate aminotransferase, ALT alanine transaminase, AF atrial fibrillation, CK creatine kinase, CRP C-reactive protein, EKG electrocardiogram, HCQ hydroxychloroquine, LDH lactate dehydrogenase

**Table 3** Clinical, laboratory, treatment, and outcome of COVID-19-related GBS and Miller-Fisher syndrome

| References                                 | Age/<br>sex | Preceding illness                                    | Time to<br>GBS                   | Symptoms/signs  | Lab tests   | Nerve conduction test   | Treatment/outcome  |
|--|-------------|--|----------------------------------|---|---|---|--|
| Alberti et al./July 2020 [32]              | 71/M        | Fever  | NA                               | Paraesthesias in all 4 limbs, areflexic flaccid quadriparesis, dyspnoea                 | Oropharyngeal swab for RT-PCR SARS-CoV-2-positive, CSF-albumin-cells diss., CT chest—B/L ground-glass opacities | AIDP  | Mechanical ventilation, HCQ, lopinavir, ritonavir, IVIG/died       |
| Farzi et al./June 2020 [33]                | 41/M        | Fever, cough, dyspnea                                | 17 days                          | Parasthesia, quadriparesis  | B/L ground-glass opacities in lungs   | AIDP  | IVIG/improved  |
| Hutchins KL et al./June 2020 [34]          | 21/M        | Fever, cough, dyspnea, headache, nasal congestion    | 16 days                          | Bifacial weakness, facial parasthesia, grade 4/5 power in limbs                         | Bilateral lung infiltrates, Gadolinium enhancement of bilateral 6th, 7th, and right 3rd cranial nerves          | Mixed type sensory motor polyneuropathy                           | 5-cycle plasma exchange/improved                                   |
| Webb et al./June 2020 [35]                 | 57/M        | Cough, headache, myalgia, malaise                    | 7 days                           | Sensory motor flaccid quadriparesis, areflexia  | Left lower lobe consolidation, lymphopenia, raised CRP  | Demyelinating neuropathy  | Mechanical ventilation, IVIG/improved                              |
| Kilinc et al./June 2020 [36]               | 50/M        | Dry cough  | 4 weeks                          | Sensory motor quadriparesis, bifacial paralysis   | Cranial MRI normal, faecal PCR-positive for SARS-CoV-2  | Demyelinating neuropathy  | IVIG/improved  |
| Helbok et al./June 2020 [37]               | 68/M        | Dry cough, headache, fatigue, myalgia, fever         | 14 days                          | Sensory motor quadriparesis   | Raised serum IgG, IgM for SARS-CoV-2, raised ESR, CRP, LDH, fibrinogen, B/L ground-glass opacities in lungs     | Demyelinating neuropathy  | NIV, plasma exchange/improved                                      |
| Sancho-Saldaña et al./June 2020 [38]       | 56/M        | Fever, dry cough, dyspnea                            | 15 days                          | Sensory motor quadriparesis, bifacial paralysis, oropharyngeal weakness                 | Lobar consolidation in lung, brain stem, and spinal cord leptomeningeal enhancement.                            | Demyelinating neuropathy  | IVIG/improved  |
| Oguz-Akarsu et al./June 2020 [39]          | 53/F        | No preceding infection/vaccination                   | NA                               | Dysarthria due to jaw weakness, predominant lower limb weakness                         | Ground-glass opacities lung fields, hyperintensity of post-ganglionic roots of brachial lumbar plexuses         | Demyelinating neuropathy  | HCQ, azithromycin/improved   |
| Lascano et al./June 2020 (3 patients) [40] | NA          | Typical COVID-related symptoms                       | 7, 15, and 22 days, respectively | Tetraparesis 2, tetraplegia 1, bifacial paralysis, and bulbar symptom 1                 | Lumbar root enhancement 1, CSF-albumin-cytological dissociation 2, lymphopenia 2                                | Demyelinating neuropathy 3  | IVIG 3/1 patient discharged, 1 walked with assistance, 1 bed-bound |
| Chan et al./May 2020 [41]                  | 8/M5        | Exposed to relative working in meat-processing plant | 20 days after exposure           | Bifacial paralysis, no limb weakness  | Persistent thrombocytosis, B/L ground-glass opacities in lungs, CSF-albumin-cytological dissociation            | Absent blink reflex bilateral, absent F-wave in left tibial nerve | IVIG/some improvement  |
| Riva et al./May 2020 [42]                  | In six-ties | Fever, headache, myalgia, anosmia, ageusia           | 20 days                          | Sensory motor quadriparesis, bifacial paralysis, dysarthria, dysphagia                  | B/L ground-glass opacities lungs, raised acute-phase reactants, SARS-CoV-2 IgG-positive                         | Demyelinating neuropathy  | Mechanical ventilation, IVIG/slow improvement                      |
| Zhao et al./May 2020 [43]                  | 61/F        | No preceding illness                                 | Not known                        | Acute paraparesis, areflexic ascending quadriparesis, sensory deficit in hands and feet | CSF-albumin-cells diss. thrombocytopenia, lymphocytopenia, oropharyngeal swab for RT-PCR SARS-CoV-2-positive    | AIDP  | IVIG, lopinavir, ritonavir, arbidol/recovered                      |
| Scheidt et al./May 2020 [44]               | 54/F        | Hypo-osmia, dysgeusia                                | 14 days                          | Acute areflexic flaccid paraparesis, tingling sensations in all 4 limbs                 | Oropharyngeal swab for RT-PCR SARS-CoV-2-positive, CSF-albumin-cells diss., negative SARS-CoV-2 RT-PCR          | AIDP  | IVIG/recovered   |

Table 3 (continued)

| References                          | Age/<br>sex | Preceding illness                                | Time to<br>GBS | Symptoms/signs   | Lab tests   | Nerve conduction test  | Treatment/outcome  |
|-------------------------------------|-------------|--|----------------|--|---|--|--|
| Ottaviani<br>et al./May 2020 [45]   | 66/F        | Fever, cough                                     | 10 days        | Acute areflexic paraparesis,<br>falls, facial nerve palsy  | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2 positive,<br>CSF-albumin-cells diss., negative<br>SARS-CoV-2 RT-PCR, CT chest—<br>B/L ground-glass opacities   | Absent F waves,<br>prolonged distal<br>latencies, reduced<br>distal CMAP<br>amplitude, slightly<br>reduced conduction<br>velocities (AIDP) | Mechanical ventilation,<br>IVIg, lopinavir,<br>ritonavir/poor              |
| Caamaño<br>et al./May 2020 [46]     | 61/M        | Fever, cough                                     | 10 days        | Right facial palsy-LMN<br>followed by left facial<br>palsy, absent blink reflex  | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2 positive, CSF—mildly<br>raised protein, CT chest—B/L pneu-<br>monia  | Not done   | HCC, lopinavir, ritonavir,<br>prednisolone/minimal<br>improvement          |
| Chan et al./May 2020<br>[47]        | 68/M        | Fever, URTI                                      | 18 days        | B/L hands and feet<br>paraesthesia, ataxia,<br>areflexic flaccid<br>paraparesis, B/L facial<br>palsy, dysarthria, dyspha-<br>gia                 | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2-positive,<br>CSF-albumin-cells diss., negative<br>SARS-CoV-2 RT-PCR, CT chest—<br>B/L ground-glass opacities   | Not done   | Plasmapheresis/progressive<br>improvement                                  |
| Bigaut et al./Sep.<br>May 2020 [48] | 84/M        | Fever  | 23 days        | B/L hands and feet<br>paraesthesias, areflexic<br>flaccid quadriparalysis, B/L<br>facial palsy, respiratory<br>failure, dysautonomia             | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2-positive, elevated GM2<br>IgM/IgG antibodies,<br>CSF-albumin-cells diss., negative<br>SARS-CoV-2 RT-PCR, CT chest—<br>B/L ground-glass opacities   | Not done   | Plasmapheresis, mechanical<br>ventilation, IVIG/residual<br>weakness       |
| Bigaut et al./Sep.<br>May 2020 [48] | 48/M        | Cough, asthenia,<br>myalgia, anosmia,<br>ageusia | 21 days        | Flaccid paraparesis,<br>generalized areflexia,<br>lower limb and distal<br>upper limb paresthesia,<br>ataxia, facial palsy                       | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2-positive,<br>CSF-albumin-cells diss., negative<br>SARS-CoV-2 RT-PCR,<br>MRI-radicitis and plexitis on both<br>brachial and lumbar plexus; multiple<br>cranial neuritis (in nerves III, VI, VII,<br>and VIII) CT chest-ground-glass<br>opacities in B/L lung fields | AIDP   | IVIg/progressive<br>improvement  |
| Assini et al./May 2020<br>[49]      | 70/F        | Anosmia, ageusia,<br>diarrhoea,<br>myalgia       | 10 days        | Flaccid tetraparesis,<br>generalized areflexia,<br>forelimb paresthesia,<br>respiratory failure  | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2-positive,<br>CSF-albumin-cells diss., negative<br>SARS-CoV-2 RT-PCR, CT chest—<br>B/L ground-glass opacities   | AIDP   | IVIg, NIV/progressive im-<br>provement                                     |
| Assini et al./May 2020<br>[49]      | 55/M        | Fever, cough,<br>anosmia, ageusia,<br>dyspnoea   | 20 days        | B/L ptosis, dysphagia,<br>dysphonia, B/L masseter<br>weakness, B/L hypoglos-<br>sal nerve palsy,<br>hyporeflexia in B/L upper<br>and lower limbs | Oropharyngeal swab for RT-PCR<br>SARS-CoV-2-positive, raised ferritin,<br>LDH, lymphocytopenia,<br>CSF-increased IgG/Alb ratio,<br>oligoclonal bands present in CSF and<br>serum  | AIDP   | Mechanical ventilation,<br>arbidol, lopinavir,<br>ritonavir, IVIG/improved |
|                                     | 60/M        |  | 20 days        |  |   | AMSAN  |  |

**Table 3** (continued)

| References                            | Age/<br>sex | Preceding illness   | Time to<br>GBS | Symptoms/signs  | Lab tests  | Nerve conduction test                      | Treatment/outcome  |
|---------------------------------------|-------------|---|----------------|---|--|--|--|
|                                       |             | Fever, cough,<br>dyspnoea                                     |                | Acute areflexic paraparesis,<br>autonomic dysfunction   | Oropharyngeal swab for RT-PCR<br>SARS-CoV-2-positive, raised ferritin,<br>LDH, lymphocytopenia,<br>CSF-increased IgG/Alb ratio,<br>oligoclonal bands present in CSF and<br>serum, CT chest—interstitial pneumo-<br>nia                                 |  | Mechanical ventilation,<br>HCQ, tocilizumab,<br>IVIg/improved                        |
| Gigli et al./May 2020<br>[50]         | 53/M        | Fever, diarrhoea  | NA             | Parasthesias, ataxia  | SARS-CoV-2 IgG/IgM-positive in blood<br>and CSF, CSF-albumin-cell diss., CT<br>chest—B/L ground-glass opacities  | AIDP                                       | NA/NA  |
| Arnaud et al./May 2020<br>[51]        | 64/M        | Fever, cough,<br>dyspnoea,<br>diarrhoea                       | 21 days        | Acute areflexic flaccid<br>paraparesis, hypoesthesia  | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2-positive,<br>CSF-albumin-cells diss., CT<br>chest-diffuse GGO with crazy paving<br>appearance   | AIDP                                       | Azithromycin, HCQ,<br>IVIg/improved  |
| Rana et al./May 2020<br>[52]          | 54/M        | Rhinorrhea,<br>odynophagia,<br>fever, chills, night<br>sweats | 2 weeks        | Quadriparesis, bifacial<br>weakness, mild<br>ophthalmoparesis,<br>difficulty in urination   | B/L basal lungs infiltrates/atelectasis  | Demyelinating<br>neuropathy                | HCQ, azithromycin, oral<br>vancomycin/improving                                      |
| Su et al./May 2020 [53]               | 72/M        | Diarrhoea, anorexia,<br>chills, no fever                      | 6 days         | Ascending sensory motor<br>quadriparesis,<br>dysautonomia, SIADH  | CSF-albumin-cytological dissociation,<br>bibasilar atelectasis with consolidation  | Demyelinating<br>neuropathy                | Mechanical ventilation,<br>antibiotics/persistent<br>weakness                        |
| Pfeferkorn<br>et al./May 2020 [54]    | 51/M        | Fever, dry cough,<br>fatigue                                  | 14 days        | Progressive areflexic flaccid<br>quadriparesis, sensory loss<br>in all extremities, B/L fa-<br>cial and hypoglossal<br>paresis, respiratory failure | Oropharyngeal swab for RT-PCR<br>SARS-CoV-2-positive,<br>CSF-albumin-cells diss., CT chest—<br>B/L interstitial infiltrates, MRI<br>spine-contrast enhancement of the spi-<br>nal nerve roots at all levels of the spine<br>including the cauda equina | AIDP                                       | Mechanical ventilation,<br>IVIg, plasma<br>exchange/poor with re-<br>sidual weakness |
| Sedaghat Z et al. April,<br>2020 [55] | 65/M        | Cough, fever,<br>dyspnoea                                     | 14 days        | Areflexic ascending<br>quadriparesis, facial<br>diplegia  | Oropharyngeal swab RT-PCR<br>SARS-CoV-2-positive, CT chest:<br>consolidations, ground-glass opacities<br>in both lungs   | AMSAN                                      | Lopinavir, ritonavir, HCQ,<br>azithromycin,<br>IVIg/improved                         |
| Toscano G et al./April<br>2020 [56]   | 77/F        | Fever, cough,<br>ageusia                                      | 7 days         | Paresthesia hands/feet<br>areflexic quadriparesis,<br>facial palsy, respiratory<br>failure  | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2 positive,<br>lymphocytopenia, CSF-albumin-cells<br>dissociation, antganglioside Ab—<br>negative, MRI spine-enhancement of<br>caudal nerve roots, CT chest—<br>interstitial pneumonia                      | AMSAN, fibrillation<br>potentials on EMG + | 2 cycles of IVIG/poor<br>outcome, residual<br>weakness, and dysphagia                |
|                                       | 23/M        | Fever, pharyngitis  | 10 days        | Lower limb paressthesia,<br>facial diplegia, areflexia,<br>ataxia   | Nasopharyngeal swab for RT-PCR<br>SARS-CoV-2-positive,<br>lymphocytopenia, CSF-albumin-cells   | AMSAN, fibrillation<br>potentials on EMG   | IVIg/improvement   |

Table 3 (continued)

| References                           | Age/<br>sex | Preceding illness           | Time to<br>GBS | Symptoms/signs   | Lab tests  | Nerve conduction test                   | Treatment/outcome  |
|--------------------------------------|-------------|-----------------------------|----------------|--|--|---|--|
|                                      |             |                             |                |  | diss., MRI head-enhancement facial nerves, CT chest—normal   |   |  |
|                                      | 55/M        | Fever, cough                | 10 days        | Lower limb weakness, paresthesia, neck pain, areflexic quadriparesis, facial palsy, respiratory failure          | Nasopharyngeal swab for RT-PCR SARS-CoV-2-positive, lymphocytopenia, CSF-albumin-cells dissociation, antitanglioside Ab—negative, MRI spine-enhancement of caudal nerve roots, CT chest—interstitial pneumonia | AMAN, fibrillation potentials on EMG +  | 2 cycles of IVIG/poor outcome, residual weakness         |
|                                      | 76/M        | Cough, hyposmia             | 5 days         | Lumbar pain and lower limb weakness, areflexic quadriparesis, ataxia   | Nasopharyngeal swab for RT-PCR SARS-CoV-2-positive, lymphocytopenia, CSF—normal, MRI spine and head—normal, CT chest—normal  | AIDP, no fibrillation potentials on EMG | IVIG/ poor, mild improvement                             |
|                                      | 61/M        | Cough, ageusia, anosmia     | 7 days         | Lower limb weakness, paresthesia, areflexic paraparesis, facial palsy, respiratory failure                       | Nasopharyngeal swab for RT-PCR SARS-CoV-2-negative, SARS-CoV-2 IgG-positive lymphocytopenia, CSF—normal, antitanglioside Ab—negative, MRI spine—normal, CT chest—interstitial pneumonia                        | AIDP, fibrillation potentials on EMG +  | IVIG, plasma exchange/poor outcome, ventilator-dependent |
| Virani et al./April 2020 [57]        | 54/M        | Fever, dry cough            | 10 days        | Numbness and weakness in B/L lower limbs, areflexic quadriparesis  | Nasopharyngeal swab for RT-PCR SARS-CoV-2-positive, MRI spine—normal, CT chest—B/L basilar opacities   | Not done                                | Mechanical ventilation, IVIG, HCQ/improved               |
| Padroni et al./April 2020 [58]       | 70/F        | Fever, dry cough            | 24 days        | Hands and feet paraesthesias, gait difficulties  | Nasopharyngeal swab for RT-PCR SARS-CoV-2-positive, CSF-albumin-cell diss., CT chest—B/L ground-glass opacities  | AIDP                                    | Mechanical ventilation, IVIG/poor                        |
| Coen et al./April 2020 [59]          | 70/M        | Fatigue, myalgia, dry cough | 10 days        | Paraesthesias, distal allodynia, urinary retention, constipation, areflexic flaccid paraparesis                  | Nasopharyngeal swab for RT-PCR SARS-CoV-2 positive, CSF-albumin-cells diss., negative SARS-CoV-2 RT-PCR, CT chest—B/L ground-glass opacities   | AIDP                                    | IVIG/improved  |
| El Omani et al./April 2020 [60]      | 70/F        | Fever, dry cough            | 3 days         | Acute flaccid areflexic quadriparesis  | Oropharyngeal swab for RT-PCR SARS-CoV-2-positive, CSF-albumin-cells diss., CT chest-ground-glass opacities in the left lung   | AMSAN                                   | IVIG, HCQ, azithromycin/improved                         |
| Marta-Enguita et al./April 2020 [61] | 76/F        | Fever, cough                | 8 days         | Lower backache with radiation to B/L lower limbs, progressive areflexic tetraparesis, distal-onset paraesthesia, | Oropharyngeal swab for RT-PCR SARS-CoV-2-positive, CSF-NA, CT chest—consolidation  | NA                                      | Mechanical ventilation/died                              |



**Table 3** (continued)

| References                               | Age/<br>sex | Preceding illness               | Time to<br>GBS | Symptoms/signs  | Lab tests  | Nerve conduction test              | Treatment/outcome      |
|--|-------------|---------------------------------|----------------|---|--|------------------------------------|------------------------|
| <b>Miller-Fisher syndrome</b>            |             |                                 |                |   |  |                                    |                        |
| Reyes-Bueno et al./June 2020 [62]        | 51/F        | Diarrhoea, odynophagia, cough   | 10 days        | dysphagia, respiratory failure<br>Quadriceps, left lateral rectus palsy, bifacial palsy, dysautonomia                   | CSF-albumin-cytological dissociation   | Demyelinating neuropathy           | IVIg/improving         |
| Fernández-Domínguez et al./May 2020 [63] | 74/F        | Fever, URTI                     | 12–15 days     | Progressive gait impairment, areflexia, blurring of vision  | Nasopharyngeal swab for RT-PCR SARS-CoV-2-positive, CSF-albumin-cells diss., negative SARS-CoV-2 RT-PCR                | Slight F-wave delay in upper limbs | IVIg/improved          |
| Lantos et al./May 2020 [64]              | 36/M        | Fever, chills, myalgia          | 4 days         | Left eyelid drooping, blurry vision, paraesthesia in both legs, left CN 3 palsy, B/L 6th CN palsy, ataxia, hyporeflexia | Nasopharyngeal swab for RT-PCR SARS-CoV-2-positive, MRI—enlargement with contrast enhancement of left oculomotor nerve | NA                                 | IVIg, HCQ/improved     |
| Gutiérrez-Ortiz et al./April 2020 [65]   | 50/M        | Fever, headache, cough, malaise | 5 days         | Anosmia, ageusia, right internuclear ophthalmoparesis, right fascicular oculomotor palsy, ataxia, areflexia             | Nasopharyngeal swab for RT-PCR SARS-CoV-2 positive, CSF-albumin-cells diss., negative SARS-CoV-2 RT-PCR                | NA                                 | IVIg/improved          |
|  | 39/M        | Fever, diarrhoea                | 3 days         | Ageusia, B/L abducens palsy, areflexia  | Nasopharyngeal swab for RT-PCR SARS-CoV-2-positive, CSF-albumin-cells diss., negative SARS-CoV-2 RT-PCR                | NA                                 | Acetaminophen/improved |

*AIDP* acute inflammatory demyelinating polyneuropathy, *AMAN* acute motor-axonal neuropathy, *AMSAN* acute motor-sensory axonal neuropathy, *CSF* cerebrospinal fluid, *EMG* electromyography, *ESR* erythrocyte sedimentation rate, *HCQ* hydroxychloroquine, *IgG* immunoglobulin G, *IgM* immunoglobulin M, *IVIg* intravenous immunoglobulin, *NA* not available, *RT-PCR* reverse transcriptase polymerase chain reaction, *URTI* upper respiratory tract infection

**Table 4** Frequency of various demographic, clinical, and electrophysiological features and good outcome in patients with COVID-19-related GBS

| Feature  | Frequency  |
|--|--|
| Number   | 39   |
| Age (data available in 36 patients)                  | 21–85 years, mean = 60.55, median = 61, mode = 70    |
| Males (data available in 35 patients)                | 26 (74.28%)  |
| Hyposmia/ageusia                                     | 6 (15.4%)/7 (17.9%)                                  |
| Time to onset of GBS (data available in 35 patients) | 3–28 days, mean = 13.91 days, median = 14, mode = 10 |
| Bifacial paralysis                                   | 18 (46.15%)  |
| Other cranial neuropathies                           | 9 (23.07%)   |
| Respiratory involvement                              | 17 (43.58%)  |
| Demyelinating/axonal (data available in 32 patients) | 24 (75%)/7 (22%)                                     |
| Outcome (data available in 38 patients)              | GOOD = 25 (65.8%), POOR = 11 (28.9%), DIED = 2 (5.3) |

## Guillain-Barré syndrome and Miller-Fisher syndrome

Recently, 39 patients with GBS and 5 patients with MFS secondary to COVID-19 were published. Most of the reports were from China, Italy, and the USA. The demographic profile, frequency of clinical features, electrophysiological features, and good outcome are described in Table 3. GBS and MFS were more frequent in elderly people. Time to onset of GBS/MFS ranged from 3 days to 4 weeks of onset of COVID-19 symptoms. Majority of patients had para-infectious and minority had post-infectious GBS/MFS. Upper respiratory tract symptoms were the usual preceding symptoms. Hyposmia and ageusia were distinctive features seen in COVID-19 patients unlike the typical GBS where these olfactory symptoms are not seen. Most patients had ascending or lower limb areflexic weakness that later on progressed and involved bifacial weakness and other cranial neuropathies. Unlike typical GBS, respiratory failure secondary to lung involvement was common in GBS patients secondary to COVID-19. Majority of patients had severe demyelinating type of neuropathy. CSF-albumin-cytological dissociation was frequently noticed. SARS-CoV-2 RT-PCR was not detected in the CSF of the patients subjected to the test. Most patients with lung pathologies required mechanical ventilation and had a poor outcome in the form of either prolonged ventilatory stay, residual weakness, or death.

Five patients with MFS (age range 36–74 years, 3 males) presented with preceding upper respiratory symptoms (2 patients) and diarrhoea (1 patient). All three patients had gait difficulty, ataxia, and areflexia. One patient had visual blurring and 2 patients had ophthalmoparesis. Two patients had preceding ageusia/hyposmia. Four patients received intravenous immunoglobulin. All five patients improved.

## Neuropathy

Three reports of 6 patients with COVID-19-related neuropathy were published [66–68]. Authors claimed that the neuropathy in their patients was different from GBS. Ghiasvand et al. reported a 68-year-old female with symmetrical lower motor neuron quadriplegia after an initial upper respiratory involvement. Due to respiratory involvement, patient died and electrophysiological tests could not be performed [66]. Abdelnour et al. reported a 69-year-old male with lower limb areflexic weakness and gait ataxia without any COVID-19-related preceding symptoms. His RT-PCR from a nasopharyngeal swab was positive for SARS-CoV-2. Electrophysiology tests were not performed. The patient improved spontaneously. In absence of nerve conduction tests, type of neuropathy could not be determined in both cases [67]. Chaumont et al. presented four patients (age range 52 to 72 years, all males), who presented with CNS symptoms along with quadriplegia after or during the weaning stage from the mechanical ventilator [68]. All patients had ARDS secondary to COVID-19 infection, and they developed neurological features after an interval of 12 to 20 days of initial COVID-19 symptoms. All patients had comorbid illnesses like diabetes mellitus in three, hypertension in two, urothelial cancer in one, and obstructive sleep apnoea in one patient. Three patients had evidence of demyelinating polyradiculoneuropathy whereas one patient had denervation in limbs suggestive of axonal neuropathy. One patient had asymmetrical neuropathy whereas the rest of the patients had symmetrical neuropathy. All patients had dysautonomia and action myoclonus, a feature not seen in critical-illness neuropathy.

**Table 5** Neuropathy in COVID-19 patients

| Reference/<br>country            | Type   | Age/<br>sex | Clinical presentation  | Respiratory<br>involvement | Blood parameters/<br>RT-PCR   | Electrophysiology   | Neuroimaging                                      | Treatment/outcome  |
|----------------------------------|--|-------------|--|----------------------------|---|---|---|--|
| Ghiasvand<br>et al./Iran<br>[66] | Symmetrical<br>polyneuropathy                      | 68/F        | Fever, dry cough, myalgia, B/L lower limbs<br>hypotonia with weakness with areflexia   | Ground-glass<br>opacities  | Raised creatinine,<br>CRP,<br>lymphopenia   | Not performed   | Normal  | Lopinavir/ritonavir,<br>oseltamivir, mechanical<br>ventilation, IV<br>methylprednisolone/dried                   |
| Abdelnour<br>/UK<br>[67]         | Motor<br>neuropathy                                | 69/M        | Lower limb weakness, knee/ankle areflexia,<br>gait ataxia, sensory normal  | Lower lobe<br>pneumonia    | Lymphocytopenia,<br>raised CRP, LDH,<br>ferritin                                  | Not performed   | Normal  | Spontaneous recovery   |
| Chaumont<br>/France<br>[68]      | Encephalopathy<br>with<br>peripheral<br>neuropathy | 62/M        | Confusion, memory loss, dysphagia, left<br>facial palsy, asymmetrical quadriparesis,<br>lower limb areflexia, upper limb<br>hyperreflexia, action myoclonus,<br>dysautonomia | Mild ARDS                  | Positive IgM, IgG for<br>SARS-CoV-2,<br>positive RT-PCR<br>nasopharyngeal<br>swab | Demyelinating asymmetric<br>motor<br>polyradiculoneuropathy<br>and moderate axonal<br>sensorimotor neuropathy | Right MCA<br>recent<br>stroke,<br>spine<br>normal | Hydroxychloroquine,<br>azithromycin, IVIg, rehab<br>centre after 36 days, mRS<br>2                               |
|                                  |  | 72/M        | Confusion, delusion, hallucinations, memory<br>impairment, dysphagia, slow saccades,<br>quadriparesis, hyperreflexia,<br>dysautonomia  | ARDS                       | Positive IgM, IgG for<br>SARS-CoV-2,<br>positive RT-PCR<br>nasopharyngeal<br>swab | Demyelinating asymmetric<br>motor<br>polyradiculoneuropathy<br>and moderate axonal<br>sensorimotor neuropathy | Normal<br>brain/spine<br>MRI                      | Hydroxychloroquine,<br>azithromycin, IVIg, rehab<br>center after 50 days, mRS<br>4                               |
|                                  |  | 50/M        | Confusion, delusion, hallucinations, memory<br>impairment, dysphagia, slow saccades,<br>quadriparesis, hyperreflexia,<br>dysautonomia  | ARDS                       | Positive IgM, IgG for<br>SARS-CoV-2,<br>positive RT-PCR<br>nasopharyngeal<br>swab | Lower motor neuron<br>involvement, denervation<br>of four limbs   | Normal<br>brain/spine<br>MRI                      | Hydroxychloroquine,<br>azithromycin, IVIg,<br>methyl prednisolone,<br>rehab centre after 76 days,<br>mRS 4       |
|                                  |  | 66/M        | Confusion, delusion, hallucinations, memory<br>impairment, dysphagia, slow saccades,<br>quadriparesis, hyperreflexia,<br>dysautonomia  | ARDS                       | Positive IgM, IgG for<br>SARS-CoV-2,<br>positive RT-PCR<br>nasopharyngeal<br>swab | Demyelinating motor<br>polyradiculoneuropathy   | Normal<br>brain/spine<br>MRI                      | Hydroxychloroquine,<br>azithromycin, IVIg,<br>methyl prednisolone,<br>discharged to home after<br>40 days, mRS 2 |

ARDS acute respiratory distress syndrome, CRP C-reactive protein, IVIg intravenous immunoglobulin, IgM immunoglobulin M, IgG immunoglobulin G, Mrs modified Rankin Scale, MCA middle cerebral artery, MRI magnetic resonance imaging

**Table 6** Patients with olfactory/gustatory dysfunction and isolated cranial neuropathy secondary to COVID-19 infection

| Type                                | Reference/country   | Age/sex                              | Clinical presentation  | Respiratory involvement | Blood parameters | Chest imaging | Neuroimaging | Treatment/outcome   |
|-------------------------------------|---|--------------------------------------|--|-------------------------|------------------|---------------|--------------|---|
| Olfactory and gustatory dysfunction | Altin et al. COVID-19 cases 81, normal controls 40 [71]                       | Cases 18–95, controls 18–90          | Olfactory complaints Cases—61.7% (50)<br>Controls—none<br>Gustatory dysfunction Cases—27.2% (22)   | NA                      | NA               | NA            | NA           | NA  |
|                                     | Gómez-Iglesias <i>N</i> = 909 (online survey) [72]                            | Mean age 34, females 68.9%           | Ageusia (581, 64.1%), hyposgeusia (256, 28.2%), dysgeusia (22, 2.4%), anosmia (752 82.8%), hyposmia (142, 15.6%), and dysosmia (8, 0.9%) | NA                      | NA               | NA            | NA           | NA  |
|                                     | Sayin et al. (telephonic survey)  | Mean 38.63 ± 10.0                    | Impairment of smell/taste COVID +VE 46 (71.9%)<br>COVID -VE 17 (26.6%)   | NA                      | NA               | NA            | NA           | NA  |
|                                     | URTI cases ( <i>N</i> = 128)  | 8.37, 5% males                       | hyposmia/parosmia, hyposgeusia/dysgeusia more in COVID +VE   | NA                      | NA               | NA            | NA           | NA  |
|                                     | COVID +VE 64, COVID -VE 64 [73]   |                                      |  |                         |                  |               |              |   |
|                                     | Lee et al./ <i>N</i> = 1345 (102 COVID +VE, 1243 -VE, sampled 1:3 ratio) [74] | +VE 38, -VE 43 (median)              | Anosmia/hyposmia COVID +VE 41.1%<br>COVID -VE 4.2%<br>Dysgeusia/ageusia COVID +VE 46.4%<br>COVID -VE 5.6%                                | N/A                     | N/A              | N/A           | N/A          | N/A   |
|                                     | Marchese-Ragona et al. ( <i>N</i> = 6)/Italy [75]                             | 24–50 years/4F, 2M                   | Hyposmia and hyposgeusia in all, fever and cough in 1 patient, myalgia in 2 patients   | No                      | NA               | NA            | NA           | Conservative/improved   |
|                                     | Lechien et al. ( <i>N</i> = 417)/Europe [76]                                  | Mean age = 36.9 year-<br>s/63.1% F   | 88.8% gustatory dysfunction, 85.6% olfactory dysfunction, others symptoms—fever, cough   | No                      | NA               | NA            | NA           | Paracetamol, NSAIDS, nasal saline irrigation, nasal steroids/favourable                   |
|                                     | Luers et al./Germany [77]   | Mean age = 38 year-<br>s/43.1% F     | 73.6% hyposmia, 69.4% hyposgeusia, 50% fever, 75% cough, 62.5% sore throat, 70.8% myalgia, 77.8% headache                                | No                      | NA               | NA            | NA           | NA/NA   |
|                                     | Vaira et al./Italy <i>N</i> = 345 [78]  | Mean age 48.5 year-<br>s/42.3% Males | Self-reported olfactory/gustatory disturbance 256 (74.2%), combined 79.3%, isolated olfactory 8.6%, isolated gustatory 12.1%             | 48.4%                   | NA               | NA            | NA           | Self-reported complete regression for smell (31.3%) and taste (50.4%) at the time of test |
|                                     | Qui C, et al./multicentre, <i>n</i> = 394 [79]                                | Median age 39 year-<br>s/57% males   | 161/394, 41% olfactory/gustatory dysfunction, only olfactory 16%, only gustatory 2%  | 66%                     | NA               | NA            | NA           | Olfactory/gustatory function improved in 44%  |
|                                     | Biadsee et al./Israel <i>n</i> = 128 [80]                                     | Mean age 36.25                       | Olfactory dysfunction 67%, anosmia 19.5%, impaired taste 52%, dry mouth  | NA                      | NA               | NA            | NA           | NA  |

**Table 6** (continued)

| Type                                  | Reference/country  | Age/sex   | Clinical presentation  | Respiratory involvement | Blood parameters   | Chest imaging                           | Neuroimaging  | Treatment/outcome   |
|---------------------------------------|--|---|--|-------------------------|--|---|---|---|
|                                       | Kosugi et al./Brazil <i>n</i> = 253 (145 COVID-19-positive) [81] | 72 patients/ males 58 Mean age 36 year- s/59.1% females | 72 patients, facial pain 26%, masticatory muscle pain 11% 145 COVID-19 patients had sudden olfactory dysfunction   | NA                      | NA   | NA                                      | NA  | Total recovery 52.6%. COVID-19-positive patients took longer time for recovery as compared with COVID-19-negative (15 days vs. 10 days) |
| Ophthalmoparesis                      | Dinkin et al./USA [82]   | 36/M  | Fever, cough, myalgia, left ptosis, diplopia, B/L distal paresthesia, partial left oculomotor palsy, B/L abducens palsies  | No                      | Leukopenia   | Normal                                  | T2 hyperintensity and enlargement of left oculomotor nerve with enhancement | IVIg, HCQ/partial improvement   |
|                                       |  | 71/F  | Fever, cough, painless diplopia, right abducens palsy  | Yes                     | Lymphopenia  | B/L opacities                           | Enhancement of optic nerve sheaths and posterior tendon capsules            | HCQ/improved  |
|                                       | Oliveira/Brazil [83]   | 69/M  | Fever, cough, dyspnea, chest pain, abdominal pain, binocular diplopia, stabbing occipital headache, B/L trochlear nerve palsies                                      | Yes                     | Raised ESR   | B/L                                     | ground-glass opacities  | s/o vasculitis of the vertebrobasilar system  |
| IV                                    |  |   | Facial palsy   | Facial palsy            | Wan et al./China [84]  | 65/F                                    | Pain in left mastoid region, left facial drooping                           | No  |
| Normal                                | Ground-glass shadows in right lower lung                         | Normal  | Arbidol, ribavirin/improved  |                         |  |   |   |   |
| Glossopharyngeal and vagal neuropathy | Aoyagi et al./Japan [85]   | 70/M  | Ageusia, soar throat, cough fever, diarrhoea. 20 days later developed abnormal throat sensation and oropharyngeal dysphagia, absent gag and absent throat sensations | Yes                     | Elevated TLC and ESR   | Ground-glass opacities both lung fields | NA  | Mechanical ventilation, antibiotics, anti-viral drugs, dysphagia rehabilitation/improving   |
| Trigeminal neuropathy                 | de Freitas Ferreira et al./Brazil [86]                           | 39/M  | Left orofacial herpes zoster, left trigeminal neuralgia, fatigability, diarrhoea,  | No                      | Varicella-Zoster IgM-positive, nasopharyngeal swab-positive for SARS-CoV-2 | NA                                      | Left trigeminal nerve enhancement   | IV acyclovir/improved   |

ESR erythrocyte sedimentation rate, HCQ hydroxychloroquine, IVIG intravenous immunoglobulins, IgM immunoglobulin M, NA not available, TLC total leukocyte count

## Olfactory and gustatory dysfunction

Olfactory and gustatory dysfunction is accepted as an early symptom of COVID-19 infection. In a review of 24 studies by Mehraeen et al., anosmia, hyposmia, ageusia, and dysgeusia was a presenting feature in majority of the studies [69]. They found anosmia to be the most common olfactory/gustatory symptom. They concluded that SARS-CoV-2 may infect neural and oral tissue and thereby present with olfactory and gustatory symptoms. Another review by Kang et al. (21 studies) had similar observations [70]. They found that the use of intranasal or oral steroids enhanced the recovery of COVID-19-related olfactory/gustatory dysfunction [70]. We found 11 studies that specifically evaluated gustatory and olfactory functions in patients with COVID-19 infection [71–81]. Majority of patients had olfactory/gustatory dysfunction in addition to other symptoms like fever, cough, sore throat, and headache. The presence of olfactory/gustatory symptoms were not related to the severity of disease but related to the duration chemosensitive symptoms [78]. More patients were found to have chemosensitive dysfunction when examined with standard tests as compared with those who self-reported symptoms. By second week, 30 to 50% patients reported regression of olfactory and gustatory symptoms [78].

In an autopsy study of two patients that died of COVID-19 infection (one had anosmia as early feature), authors found inflammation and axonal damage in the olfactory bulb explaining the olfactory symptoms [94]. In both cases, olfactory striae were normal. Other finding was perivascular leukocyte infiltration in the basal ganglia. The olfactory bulb edema has also been demonstrated on cranial MRI of patients with COVID-19 infection [95]. His anosmia and dysgeusia improved by 14 days and olfactory bulb edema also subsided on repeat MRI at 24 days of illness. In a study of 18 COVID-19 patients who underwent Butanol threshold test and smell identification tests, the biopsies of the nasal mucosa revealed CD68 macrophages harbouring SARS-CoV-2 antigen in their stroma [96].

## Cranial neuropathy

Various cranial neuropathies are described in patients with COVID-19 infection in relation to encephalopathy/encephalitis or GBS. However, isolated cranial neuropathies have also been described. Dinkin et al. described a 36-year-old male with constitutional symptoms, diplopia secondary to left 3rd, and bilateral 6th nerve palsy [82]. MRI showed hyperintensity on T2-weighted sequence and gadolinium enhancement of left 3rd cranial nerve. He showed partial improvement on intravenous immunoglobulin. Another 71-year-old female presented with painless right 6th cranial nerve palsy. She had gadolinium enhancement of optic nerve sheath.

She showed spontaneous improvement in diplopia. Oliveira RMC et al. reported a 69-year-old male with stabbing occipital pain and diplopia secondary to trochlear nerve palsy [83]. He had evidence of vertebrobasilar vasculitis that showed improvement on intravenous methylprednisolone. Another patient reported by Wan et al. had left facial palsy along with pain in left mastoid region. He improved with anti-viral drugs [84]. Glossopharyngeal, vagus, and trigeminal neuropathy (with Herpes Zoster co-infection) have also been described in patients with COVID-19 [85, 86]. All these patients with cranial neuropathies showed lung involvement secondary to COVID-19 infection.

## Patho-mechanism of nervous tissue involvement

### Neuronal affinity and propagation

ACE 2 is widely expressed on nervous tissue cells like neurons, astrocytes, and oligodendrocytes. Substantia nigra, ventricles, middle temporal gyrus, posterior cingulate cortex, and olfactory bulb express ACE-2 receptor in high concentrations. In addition, respiratory epithelium, lung parenchyma, vascular endothelium, kidney cells, and intestinal epithelium also express ACE-2 [97, 98]. Virus may gain entry to nervous tissue from vascular endothelial cells. Once inside the nerve cell, SARS-CoV-2 can alter the cellular transport function to facilitate its transmission from one neuron to another [99, 100].

Since SARS-CoV-2 is a respiratory virus, the virus particles have been shown in the CD 68 macrophages in the biopsy of nasal tissues from patients presenting with COVID-19-related olfactory dysfunction [96]. Patients with olfactory dysfunction may have inflammation and edema of olfactory bulb [94, 95]. In animal studies, it has been shown that coronavirus may utilize olfactory pathway to gain entry into central nervous system [101]. Neuronal changes have been detected in hypothalamus and cortex of SARS-CoV victims [102]. Retrograde transmission of the virus from peripheral nerve terminals through nerve synapses with the help of neural proteins dynein and kinesin have also been postulated [98]. SARS-CoV-2 RNA has also been demonstrated in the CSF [98].

### Mechanisms of involvement of peripheral nerves

The mechanism of involvement of peripheral nervous system is not fully understood. It is mostly thought to be immune-mediated. In patients with rapid evolution of GBS after the onset of COVID-19 symptoms, direct cytotoxic effects of virus on peripheral nerves is a postulated mechanism. Guillain-Barré syndrome (GBS) is usually considered an immune-mediated disease of peripheral nerve myelin sheath or

Schwann cells. The glycoproteins on the surface of the virus resemble with glycoconjugates in human nervous tissue [55]. The antibodies formed against the viral surface glycoproteins acts against the glycoconjugates on the neural tissue. This mechanism of nerve injury is famously known as “molecular mimicry”. SARS-CoV-2 shares two hexapeptides with human shock proteins 90 and 60. Both these proteins have immunogenic potentials, and they are among the 41 human proteins associated with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy [103]. The other neuropathies reported in patients with COVID-19 may also be secondary to immune-mediated mechanisms.

### Mechanism of muscle involvement

The mechanism of myositis in COVID-19 infection is not fully understood. Skeletal muscles and other cells in the muscles like satellite cells, leukocytes, fibroblasts, and endothelial cells express ACE-2. Therefore, it is postulated that skeletal muscles are susceptible to direct muscle invasion by SARS-CoV-2 [104]. Animal studies suggest that children are more likely to get affected due to their immature muscle cells [25]. Other possible mechanisms suggested are immune complex deposition in muscles, release of myotoxic cytokines, damage due to homology between viral antigens and human muscle cells, and adsorption of viral protein on muscle membranes leading to expression of viral antigens on myocyte surface. Whether these postulated mechanisms for COVID-19-related myositis are also responsible for myalgia is also not known.

### Conclusion

SARS-CoV-2 has a special affinity for the neural tissue. Olfactory and gustatory symptoms are accepted as an early manifestation of COVID-19 infection. Olfactory bulb inflammation and edema with axonal damage in patients with COVID-19 suggest an olfactory route entry of virus to involve the brain and other cranial nerves. The SARS-CoV-2 also involves peripheral nervous system. Myalgia is one of the common early symptoms of the disease. Guillain-Barré syndrome and Miller-Fisher syndrome are increasingly being described in patients with preceding or concomitant COVID-19 disease. This points towards the involvement of peripheral nerves either by direct infection of nerves or by the mechanism of “molecular mimicry”. There are also reports of myositis and rhabdomyositis secondary to COVID-19 disease. Since muscle also expresses ACE-2 receptors, direct muscle involvement by SARS-CoV-2 is postulated in addition to immune-mediated muscle damage.

**Availability of data and material (data transparency)** All data provided with the manuscript.

**Authors' contributions** VKP conceived and wrote the manuscript. RKG revised the manuscript. AG and NT wrote tables and collected data.

### Compliance with ethical standards

**Ethical approval** The review does not require ethical clearance.

**Conflict of interest** The authors declare that they have no conflict of interests.

### References

- Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* 17:181–192
- Weiss SR, Navas-Martin S (2005) Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. *Microbiol Mol Biol Rev* 69:635–664
- Perlman S, Netland J (2009) Coronaviruses post-SARS: update on replication and pathogenesis. *Nat Rev Microbiol* 7:439–450
- Hilgenfeld R, Peiris M (2013) From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. *Antivir Res* 100:286–295
- Alshukairi AN, Zheng J, Zhao J et al (2018) High prevalence of MERS-CoV infection in camel workers in Saudi Arabia. *mBio* 9:e01985–e01918
- Natoli S, Oliveira V, Calabresi P, Maia, Pisani A (2020) Does SARS-Cov-2 invade the brain? Translational lessons from animal models. *Eur J Neurol*. <https://doi.org/10.1111/ene.14277> Published on line April 25, 2020
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 395:497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- Xu XW, Wu XX, Jiang XG et al (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series [published correction appears in *BMJ*. 368:m792. *BMJ* 368:m606. Published 2020 Feb 19. <https://doi.org/10.1136/bmj.m606>.
- Liu M, He P, Liu HG, Wang XJ, Li FJ, Chen S, Lin J, Chen P, Liu JH, Li CH (2020) Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia. *Zhonghua Jie He Hu Xi Za Zhi* 43(3):209–214. <https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.014>
- Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y (2020) COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol* 92(6):577–583
- Wang X, Liu W, Zhao J, Lu Y, Wang X, Yu C, Hu S, Shen N, Liu W, Sun Z, Li W (2020) Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China. *J Hosp Infect* S0195-6701(20):30194–30198. <https://doi.org/10.1016/j.jhin.2020.04.019>
- Wei XS, Wang XR, Zhang JC, Yang WB, Ma WL, Yang BH, Jiang NC, Gao ZC, Shi HZ, Zhou Q (2020) A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2. *J Microbiol Immunol Infect* S1684-1182(20):30107–30109. <https://doi.org/10.1016/j.jmii.2020.04.013>

13. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, Huet K, Plzak J, Horoi M, Hans S, Barillari MR (2020) Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *J Intern Med* 288:335–344. <https://doi.org/10.1111/joim.13089>
14. Lai X, Wang M, Qin C, Tan L, Ran L, Chen D, Zhang H, Shang K, Xia C, Wang S, Xu S (2020) Coronavirus disease 2019 (COVID-2019) infection among health care workers and implications for prevention measures in a tertiary hospital in Wuhan, China. *JAMA Netw Open* 3(5):e209666. Published 2020 May 1. <https://doi.org/10.1001/jamanetworkopen.2020.9666>
15. Zhu J, Zhong Z, Ji P, Pang J, Zhang J, Zhao C (2020) Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. *Fam Med Community Health* 8(2):e000406. <https://doi.org/10.1136/fmch-2020-000406>
16. Lapostolle F, Schneider E, Vianu I, Dollet G, Roche B, Berdah J, Michel J, Goix L, Chanzy E, Petrovic T, Adnet F (2020) Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. *Intern Emerg Med* 15:1–5. <https://doi.org/10.1007/s11739-020-02379-z>
17. Chen Y, Zhao M, Wu Y, Zang S (2020) Epidemiological analysis of the early 38 fatalities in Hubei, China, of the coronavirus disease 2019. *J Glob Health* 10(1):011004. <https://doi.org/10.7189/jogh-10-011004>
18. Korkmaz MF, Türe E, Dorum BA, Kılıç ZB (2020) The epidemiological and clinical characteristics of 81 children with COVID-19 in a pandemic hospital in Turkey: an observational cohort study. *J Korean Med Sci* 35(25):e236. <https://doi.org/10.3346/jkms.2020.35.e236>
19. O'Reilly GM, Mitchell RD, Wu J et al (2020) Epidemiology and clinical features of emergency department patients with suspected COVID-19: results from the first month of the COVED Quality Improvement Project (COVED-2). *Emerg Med Australas*. <https://doi.org/10.1111/1742-6723.13573>
20. Gaur A, Meena SK, Bairwa R, Meena D, Nanda R, Sharma SR, Rajawat GS (2020) Clinico-radiological presentation of COVID-19 patients at a tertiary care center at Bhilwara Rajasthan, India. *J Assoc Physicians India* 68(7):29–33
21. Aggarwal A, Shrivastava A, Kumar A, Ali A (2020) Clinical and epidemiological features of SARS-CoV-2 patients in SARI ward of a tertiary care centre in New Delhi. *J Assoc Physicians India* 68(7):19–26
22. Borku Uysal B, Ikitimur H, Yavuzer S, Islamoglu MS, Cengiz M (2020) Case report: a COVID-19 patient presenting with mild rhabdomyolysis. *Am J Trop Med Hyg* 103:847–850. <https://doi.org/10.4269/ajtmh.20-0583>
23. Valente-Acosta B, Moreno-Sanchez F, Fueyo-Rodriguez O, Palomar-Lever A (2020) Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19. *BMJ Case Rep* 13(6):e236719. <https://doi.org/10.1136/bcr-2020-236719>
24. Beydon M, Chevalier K, Al Tabaa O et al (2020) Myositis as a manifestation of SARS-CoV-2 [published online ahead of print, 2020 Apr 23]. *Ann Rheum Dis*:217573. <https://doi.org/10.1136/annrheumdis-2020-217573>
25. Suwanwongse K, Shabarek N (2020) Rhabdomyolysis as a presentation of 2019 novel coronavirus disease. *Cureus*. 12(4):e7561. <https://doi.org/10.7759/cureus.7561>
26. Zhang Q, Shan KS, Minalyan A, O'Sullivan C, Nace T (2020) A rare presentation of coronavirus disease 2019 (COVID-19) induced viral myositis with subsequent rhabdomyolysis. *Cureus*. 12(5):e8074. <https://doi.org/10.7759/cureus.8074>
27. Jin M, Tong Q (2020) Rhabdomyolysis as Potential late complication associated with COVID-19. *Emerg Infect Dis* 26(7):1618–1620. <https://doi.org/10.3201/eid2607.200445>
28. Chan KH, Farouji I, Abu Hanoud A, Slim J (2020) Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). *Am J Emerg Med* 38(7):1548.e1–1548.e3. <https://doi.org/10.1016/j.ajem.2020.05.015>
29. Gefen AM, Palumbo N, Nathan SK, Singer PS, Castellanos-Reyes LJ, Sethna CB (2020) Pediatric COVID-19-associated rhabdomyolysis: a case report. *Pediatr Nephrol* 35(8):1517–1520. <https://doi.org/10.1007/s00467-020-04617-0>
30. Ramaswamy SB, Govindarajan R (2020) COVID-19 in refractory myasthenia gravis—a case report of successful outcome. *J Neuromuscul Dis* 7(3):361–364. <https://doi.org/10.3233/JND-200520>
31. Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, David WS, Guidon A (2020) COVID-19 in patients with myasthenia gravis. *Muscle Nerve*. <https://doi.org/10.1002/mus.26918>
32. Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, Viganò M, Giovannelli G, Pirro F, Montisano DA, Appollonio I, Ferrarese C (2020) Guillain-Barré syndrome related to COVID-19 infection. *Neurol Neuroimmunol Neuroinflamm* 7(4):e741. <https://doi.org/10.1212/NXI.0000000000000741>
33. Farzi MA, Ayromlou H, Jahanbakhsh N, Bavit PH, Janzadeh A, Shayan FK (2020) Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case. *J Neuroimmunol* 346:577294. <https://doi.org/10.1016/j.jneuroim.2020.577294>
34. Hutchins KL, Jansen JH, Comer AD, Scheer RV, Zahn GS, Capps AE, Weaver LM, Koontz NA (2020) COVID-19-associated bifacial weakness with paresthesia subtype of Guillain-Barré syndrome. *AJNR Am J Neuroradiol*. <https://doi.org/10.3174/ajnr.A6654>
35. Webb S, Wallace VC, Martin-Lopez D, Yogarajah M (2020) Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. *BMJ Case Rep* 13(6):e236182. Published 2020 Jun 14. <https://doi.org/10.1136/bcr-2020-236182>
36. Kilinc D, van de Pasch S, Doets AY, Jacobs BC, van Vliet J, Garsen MPJ (2020) Guillain-Barré syndrome after SARS-CoV-2 infection. <https://doi.org/10.1111/ene.14398>
37. Helbok R, Beer R, Löscher W, Boesch S, Reindl M, Hornung R, Schiefelcker AJ, Deisenhammer F, Pfusler B (2020) Guillain-Barré syndrome in a patient with antibodies against SARS-CoV-2 [published online ahead of print, 2020 Jun 12]. *Eur J Neurol* 27:1754–1756. <https://doi.org/10.1111/ene.14388>
38. Sancho-Saldaña A, Lambea-Gil Á, Liesa JLC et al (2020) Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection. *Clin Med (Lond)*. <https://doi.org/10.7861/clinmed.2020-0213>
39. Oguz-Akarsu E, Ozpar R, Mirzayev H, Acet-Ozturk NA, Hakyemez B, Ediger D, Karli N, Pandemic Study Team (2020) Guillain-Barré Syndrome in a patient with minimal symptoms of COVID-19 infection. *Muscle Nerve* 62:E54–E57. <https://doi.org/10.1002/mus.26992>
40. Lascano AM, Epiney JB, Coen M, Serratrice J, Bernard-Valnet R, Lalive PH, Kuntzer T, Hübers A (2020) SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome [published online ahead of print, 2020 Jun 1]. *Eur J Neurol* 27:1751–1753. <https://doi.org/10.1111/ene.14368>
41. Chan JL, Ebadi H, Sama JR (2020) Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection [published online ahead of print, 2020 May 29]. *Can J Neurol Sci*:1–3. <https://doi.org/10.1017/cjn.2020.106>
42. Riva N, Russo T, Falzone YM et al (2020) Post-infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: a case report. *J Neurol*:1–3. <https://doi.org/10.1007/s00415-020-09907-z>
43. Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? *Lancet Neurol* 19(5):383–384
44. Scheidl E, Canseco DD, Hadji-Naumov A, Bereznaï B (2020) Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case



- report and review of recent literature. *J Peripher Nerv Syst* 25(2): 204–207. <https://doi.org/10.1111/jns.12382>
45. Ottaviani D, Boso F, Tranquillini E, Gapeni I, Pedrotti G, Cozzio S, Guarrera GM, Giometto B (2020) Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. *Neurol Sci* 41(6):1351–1354. <https://doi.org/10.1007/s10072-020-04449-8>
  46. Juliao Caamaño DS, Alonso Beato R (2020) Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. *J Clin Neurosci* 77: 230–232. <https://doi.org/10.1016/j.jocn.2020.05.016>
  47. Chan M, Han SC, Kelly S, Tamimi M, Giglio B, Lewis A (2020) A case series of Guillain-Barré Syndrome following Covid-19 infection in New York. *Neurol Clin Pract*. <https://doi.org/10.1212/CPJ.0000000000000800>
  48. Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, Godon A, Vouilleminot P, Kremer L, Chanson JB, de Seze J (2020) Guillain-Barré syndrome related to SARS-CoV-2 infection. *Neurol Neuroimmunol Neuroinflamm* 7(5):e785. <https://doi.org/10.1212/NXI.0000000000000785>
  49. Assini A, Benedetti L, Silvia DM, Erika S, Sette MD (2020) Two different clinical manifestation of Covid-19 related Guillain-Barré syndrome highly responsive to intravenous immunoglobulins: two Italian cases. *Research Square*. <https://doi.org/10.21203/rs.3.rs-30354/v1>
  50. Gigli GL, Bax F, Marini A, Pellitteri G, Scalise A, Surcinelli A, Valente M (2020) Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster? *J Neurol*:1–3. <https://doi.org/10.1007/s00415-020-09911-3>
  51. Arnaud S, Budowski C, Ng Wing Tin S, Degos B (2020) Post SARS-CoV-2 Guillain-Barré syndrome. *Clin Neurophysiol* 131(7):1652–1654. <https://doi.org/10.1016/j.clinph.2020.05.003>
  52. Rana S, Lima AA, Chandra R, Valeriano J, Desai T, Freiberg W, Small G (2020) Novel coronavirus (COVID-19)-associated Guillain-Barré syndrome: case report. *J Clin Neuromuscul Dis* 21(4):240–242. <https://doi.org/10.1097/CND.0000000000000309>
  53. Su XW, Palka SV, Rao RR, Chen FS, Brackney CR, Cambi F (2020) SARS-CoV-2-associated Guillain-Barré syndrome with dysautonomia. *Muscle Nerve* 62:E48–E49. <https://doi.org/10.1002/mus.26988>
  54. Pfefferkorn T, Dabitz R, von Wernitz-Keibel T, Aufenanger J, Nowak-Machen M, Janssen H (2020) Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19. *J Neurol* 267(7):1883–1884. <https://doi.org/10.1007/s00415-020-09897-y>
  55. Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associated with COVID-19 infection: a case report. *J Clin Neurosci* 76:233–235. <https://doi.org/10.1016/j.jocn.2020.04.062>
  56. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A, Micieli G (2020) Guillain-Barré syndrome associated with SARS-CoV-2. *N Engl J Med* 382(26):2574–2576. <https://doi.org/10.1056/NEJMc2009191>
  57. Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, Balaan M, Bhanot N (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection [published online ahead of print, 2020 Apr 18]. *IDCases*. 20:e00771. <https://doi.org/10.1016/j.idcr.2020.e00771>
  58. Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG, Querzani P, Callegarini C, Foschi M (2020) Guillain-Barré syndrome following COVID-19: new infection, old complication? *J Neurol* 267(7):1877–1879. <https://doi.org/10.1007/s00415-020-09849-6>
  59. Coen M, Jeanson G, Culebras Almeida LA et al (2020) Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. *Brain Behav Immun* S0889-1591(20):30698-X. <https://doi.org/10.1016/j.bbi.2020.04.074>
  60. El Otmani H, El Moutawakil B, Rafai MA et al (2020) Covid-19 and Guillain-Barré syndrome: more than a coincidence! *Rev Neurol (Paris)* 176(6):518–519. <https://doi.org/10.1016/j.neurol.2020.04.007>
  61. Marta-Enguita J, Rubio-Baines I, Gastón-Zubimendi I (2020) Fatal Guillain-Barre syndrome after infection with SARS-CoV-2. Síndrome de Guillain-Barré fatal tras infección por el virus SARS-CoV-2. *Neurologia*. 35(4):265–267. <https://doi.org/10.1016/j.nrl.2020.04.004>
  62. Reyes-Bueno JA, García-Trujillo L, Urbaneja P, Ciano-Petersen NL, Postigo-Pozo MJ, Martínez-Tomás C, Serrano-Castro PJ (2020) Miller-Fisher syndrome after SARS-CoV-2 infection. *Eur J Neurol* 27:1759–1761. <https://doi.org/10.1111/ene.14383>
  63. Fernández-Domínguez J, Ameijide-Sanluis E, García-Cabo C, García-Rodríguez R, Mateos V (2020) Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19). *J Neurol*: 1–2. <https://doi.org/10.1007/s00415-020-09912-2>
  64. Lantos JE, Strauss SB, Lin E (2020) COVID-19-Associated Miller Fisher syndrome: MRI findings. *AJNR Am J Neuroradiol* 41:1184–1186. <https://doi.org/10.3174/ajnr.A6609>
  65. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S et al (2020) Miller Fisher syndrome and polyneuritis cranialis in COVID-19. *Neurology*. 95:e601–e605. <https://doi.org/10.1212/WNL.00000000000009619>
  66. Ghasvand F, Ghadimi M, Ghadimi F, Safarpour S, Hosseinzadeh R, SeyedAlinaghi SA (2020) Symmetrical polyneuropathy in coronavirus disease 2019 (COVID-19). *IDcases*. 21:e00815. <https://doi.org/10.1016/j.idcr.2020.e00815>
  67. Abdelnour L, Eltahir Abdalla M, Babiker S (2020) COVID 19 infection presenting as motor peripheral neuropathy. *J Formos Med Assoc* 119(6):1119–1120. <https://doi.org/10.1016/j.jfma.2020.04.024>
  68. Chaumont H, San-Galli A, Martino F, Couratier C, Joguet G, Carles M, Roze E, Lannuzel A (2020) Mixed central and peripheral nervous system disorder in severe SARS-Cov-2 infection:1–7. <https://doi.org/10.1007/s00415-020-09986-y>
  69. Mehraeen E, Behnezhad F, Salehi MA et al (2020) Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence. *Eur Arch Otorhinolaryngol*:1–6. <https://doi.org/10.1007/s00405-020-06120-6>
  70. Kang YJ, Cho JH, Lee MH, Kim YJ, Park CS (2020) The diagnostic value of detecting sudden smell loss among asymptomatic COVID-19 patients in early stage: the possible early sign of COVID-19. *Auris Nasus Larynx* S0385-8146(20):30140–30141. <https://doi.org/10.1016/j.anl.2020.05.020t>
  71. Altin F, Cingi C, Uzun T, Bal C (2020) Olfactory and gustatory abnormalities in COVID-19 cases. *Eur Arch Otorhinolaryngol*:1–7. <https://doi.org/10.1007/s00405-020-06155-9>
  72. Gómez-Iglesias P, Porta-Etessam J, Montalvo T, Valls-Carbó A, Gajate V, Matías-Guiu JA, Parejo-Carbonell B, González-García N, Ezpeleta D, Láinez JM, Matías-Guiu J (2020) An online observational study of patients with olfactory and gustatory alterations secondary to SARS-CoV-2 infection. *Front Public Health* 8:243. <https://doi.org/10.3389/fpubh.2020.00243>
  73. Sayin İ, Yaşar KK, Yazici ZM (2020) Taste and smell impairment in COVID-19: an AAO-HNS Anosmia Reporting Tool-Based Comparative Study. *Otolaryngol Head Neck Surg* 194599820931820. <https://doi.org/10.1177/0194599820931820>
  74. Lee DJ, Lockwood J, Das P, Wang R, Grinspun E, Lee JM (2020) Self-reported anosmia and dysgeusia as key symptoms of coronavirus disease 2019. *CJEM*:1–8. <https://doi.org/10.1017/cem.2020.420>
  75. Marchese-Ragona R, Ottaviano G, Nicolai P, Vianello A, Carecchio M Sudden hyposmia as a prevalent symptom of

- COVID-19 infection. medRxiv. <https://doi.org/10.1101/2020.04.06.20045393>
76. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. *Eur Arch Otorhinolaryngol* 277:1–11. <https://doi.org/10.1007/s00405-020-05965-1>
  77. Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, Klein F, Lehmann C, Heindl LM (2020) Olfactory and gustatory dysfunction in Coronavirus disease 19 (COVID-19). *Clin Infect Dis* ciaa525. <https://doi.org/10.1093/cid/ciaa525>
  78. Vaira LA, Salzano G, Deiana G, De Riu G (2020) Anosmia and ageusia: common findings in COVID-19 patients. *Laryngoscope*. 130(7):1787. <https://doi.org/10.1002/lary.28692>
  79. Qiu C, Cui C, Haufort C et al (2020) Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: an international multicenter study. *Otolaryngol Head Neck Surg* 194599820934376. <https://doi.org/10.1177/0194599820934376>
  80. Biadsee A, Biadsee A, Kassem F et al (2020) Olfactory and oral manifestations of COVID-19: sex-related symptoms-a potential pathway to early diagnosis. *Otolaryngol Head Neck Surg* 194599820934380. <https://doi.org/10.1177/0194599820934380>
  81. Kosugi EM, Lavinsky J, Romano FR, Fornazieri MA, Luz-Matsumoto GR, Lessa MM, Piltcher OB, Sant'Anna GD (2020) Incomplete and late recovery of sudden olfactory dysfunction in COVID-19. *Braz J Otorhinolaryngol* S1808-8694(20):30059–30058. <https://doi.org/10.1016/j.bjorl.2020.05.001>
  82. Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, Harpe J, Greer C, Mints G, Salama G, Tsiouris AJ (2020) COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. *Neurology*. 95:221–223. <https://doi.org/10.1212/WNL.0000000000009700>
  83. Oliveira RMC, Santos DH, Olivetti BC, Takahashi JT (2020) Bilateral trochlear nerve palsy due to cerebral vasculitis related to COVID-19 infection. *Arq Neuropsiquiatr* 78(6):385–386. <https://doi.org/10.1590/0004-282x20200052>
  84. Wan Y, Cao S, Fang Q, Wang M, Huang Y (2020) Coronavirus disease 2019 complicated with Bell's palsy: a case report. *Research Square*. <https://doi.org/10.21203/rs.3.rs-23216/v1>
  85. Aoyagi Y, Ohashi M, Funahashi R, Otaka Y, Saitoh E (2020) Oropharyngeal dysphagia and aspiration pneumonia following Coronavirus disease 2019: a case report. *Dysphagia*. 1-4:545–548. <https://doi.org/10.1007/s00455-020-10140-z>
  86. de Freitas Ferreira ACA, Romão TT, Silva Macedo Y, Pupe C, Nascimento OJ (2020) COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy. *Eur J Neurol* 27:1748–1750. <https://doi.org/10.1111/ene.14361>
  87. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, Wei J, Gong Z, Zhou C, Yu H, Yu M, Lei H, Cheng F, Zhang B, Xu Y, Wang G, Dong W (2020) Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol Infect* 26(6):767–772. <https://doi.org/10.1016/j.cmi.2020.04.012>
  88. Peyronnet V, Sibiude J, Deruelle P, Huissoud C, Lescure X, Lucet J-C, Mandelbrot L, Nisand I, Vayssière C, Yazpandanah Y, Luton D, Picone O (2020) SARS-CoV-2 infection during pregnancy. Information and proposal of management care. *CNGOF. Gynecol Obstet Fertil Senol* 48(5):436–443. <https://doi.org/10.1016/j.gofs.2020.03.014>
  89. Zhang T, Sun LX, Feng RE (2020) Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. *Zhonghua Jie He He Hu Xi Za Zhi* 43(6):496–502. <https://doi.org/10.3760/cma.j.cn112147-20200311-00312>
  90. Shah SJ, Barish PN, Prasad PA et al (2020) Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a comparison of patients with and without COVID-19. Preprint. medRxiv. <https://doi.org/10.1101/2020.05.02.20082461>
  91. Corsini Campioli C, Cano Cevallos E, Assi M, Patel R, Binnicker MJ, O'Horo JC (2020) Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19. *J Clin Virol* 130:104577. <https://doi.org/10.1016/j.jcv.2020.104577>
  92. Madia F, Merico B, Primiano G, Cutuli SL, De Pascale G, Servidei S (2020) Acute myopathic quadriplegia in COVID-19 patients in the intensive care unit. *Neurology*. Advance online publication. <https://doi.org/10.1212/WNL.0000000000010280>
  93. Morley JE, Kalantar-Zadeh K, Anker SD (2020) COVID-19: a major cause of cachexia and sarcopenia? *J Cachexia Sarcopenia Muscle* 11:863–865. <https://doi.org/10.1002/jcsm.12589>. Advance online publication
  94. Kirschenbaum D, Imbach LL, Ulrich S, Rushing EJ, Keller E, Reimann RR, Frauenknecht KBM, Lichtblau M, Witt M, Thomas H, Steiger P, Adriano A, Frontzek K (2020) Inflammatory olfactory neuropathy in two patients with Covid-19. *Research Square*. <https://doi.org/10.21203/rs.3.rs-34001/v1>
  95. Laurendon T, Radulesco T, Mugnier J, Gérault M, Chagnaud C, el Ahmadi AA, Varoquaux A (2020) Bilateral transient olfactory bulbs edema during COVID-19-related anosmia. *Neurology*. 95:224–225. <https://doi.org/10.1212/wnl.0000000000009850>
  96. Chung TW, Sridhar S, Zhang AJ et al (2020) Olfactory dysfunction in Coronavirus disease 2019 patients: observational cohort study and systematic review. *Open Forum Infect Dis* 7(6): ofaa199. <https://doi.org/10.1093/ofid/ofaa199>
  97. Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 181(2):271–280.e8. <https://doi.org/10.1016/j.cell.2020.02.052>
  98. Conde Cardona G, Quintana Pájaro LD, Quintero Marzola ID, Ramos Villegas Y, Moscote Salazar LR (2020) Neurotropism of SARS-CoV 2: mechanisms and manifestations. *J Neurol Sci* 412:116824. <https://doi.org/10.1016/j.jns.2020.116824>
  99. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM (2018) Neurologic alterations due to respiratory virus infections. *Front Cell Neurosci* 12:386. <https://doi.org/10.3389/fncel.2018.00386>
  100. Dubé M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ (2018) Axonal transport enables neuron-to-neuron propagation of human Coronavirus OC43. *J Virol* 92(17):e00404–e00418. <https://doi.org/10.1128/JVI.00404-18>
  101. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S (2008) Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *J Virol* 82(15):7264–7275
  102. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong ASY (2005) Multiple organ infection and the pathogenesis of SARS. *J Exp Med* 202(3):415–424
  103. Lucchese G, Flöel A (2020) SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. *Cell Stress Chaperones*:1–5. <https://doi.org/10.1007/s12192-020-01145-6>
  104. Ferrandi PJ, Alway SE, Mohamed JS (2020) The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. *J Appl Physiol* (1985). <https://doi.org/10.1152/jappphysiol.00321.2020>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.